VANCOUVER, BC, Aug. 18, 2022 /CNW/ - HAVN Life Sciences Inc. (CNSX:HAVN.CN) (OTC:HAVLF) (FSE:5NP) (the "Company" or "HAVN Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that it has closed the initial tranche (the "First Tranche") of its financing commitment (the "Financing") by Alpha Blue Ocean ("ABO") that was previously announced on July 21, 2022. The Company intends to use the proceeds from the close of the First Tranche for general working capital purposes.
Read more at newswire.caHAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments and the Issuance of Shares for Debt
Newswire.ca - Press Release 
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/NVIDIA%20Corp%20logo%20on%20phone-by%20Evolf%20via%20Shutterstock.jpg)
/Jen-Hsun%20Huan%20NVIDIA's%20Founder%2C%20President%20and%20CEO%20by%20jamesonwu1972%20via%20Shutterstock.jpg)
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)